We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
-2.2%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$1.47B
AUM Growth
-$30.5M
Cap. Flow
+$92.4M
Cap. Flow %
6.31%
Top 10 Hldgs %
63.82%
Holding
43
New
4
Increased
16
Reduced
5
Closed
8

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$53.2M
2
CATX icon
Perspective Therapeutics
CATX
+$36.9M
3
ALKS icon
Alkermes
ALKS
+$33.7M
4
PCVX icon
Vaxcyte
PCVX
+$30.3M
5
COGT icon
Cogent Biosciences
COGT
+$25.1M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$56.2M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$54.5M
3
VERA icon
Vera Therapeutics
VERA
+$27.4M
4
KYTX icon
Kyverna Therapeutics
KYTX
+$22.7M
5
ENGN icon
enGene Therapeutics
ENGN
+$21.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.48%
2 Financials 0.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORIC icon
26
Oric Pharmaceuticals
ORIC
$1.25B
$14.1M 0.97%
2,000,000
– –
APGE icon
27
Apogee Therapeutics
APGE
$10.2B
$11.4M 0.78%
290,000
– –
CABA icon
28
Cabaletta Bio
CABA
$439M
$8.23M 0.56%
1,100,000
– –
PCSC
29
DELISTED
Perceptive Capital Solutions
PCSC
$7.54M 0.52%
+750,000
New +$7.55M
NGNE icon
30
Neurogene
NGNE
$696M
$7.28M 0.5%
200,000
– –
VTGN icon
31
VistaGen Therapeutics
VTGN
$9.29M
$5.48M 0.37%
1,575,000
– –
BBOT
32
BridgeBio Oncology
BBOT
$707M
$5.11M 0.35%
500,000
– –
AUTL
33
Autolus Therapeutics
AUTL
$386M
$4.1M 0.28%
1,178,723
-1,121,277
-49% -$4.84M
ORKA
34
Oruka Therapeutics
ORKA
$5.56B
$1.59M 0.11%
+34,527
New +$1.38M
AVTX icon
35
Avalo Therapeutics
AVTX
$976M
$499K 0.03%
+40,000
New +$519K
ACET icon
36
Adicet Bio
ACET
$72.8M
– –
-85,895
Closed -$3.23M
ADVM
37
DELISTED
Adverum Biotechnologies
ADVM
– –
-657,333
Closed -$9.29M
DBVT
38
DBV Technologies
DBVT
$807M
– –
-9,269
Closed -$69.4K
ENGN icon
39
enGene Therapeutics
ENGN
$122M
– –
-1,250,000
Closed -$21.2M
MGNX icon
40
MacroGenics
MGNX
$235M
– –
-295,020
Closed -$4.34M
SABS icon
41
SAB Biotherapeutics
SABS
$268M
– –
-183,174
Closed -$832K
KYTX icon
42
Kyverna Therapeutics
KYTX
$450M
– –
-912,189
Closed -$22.7M
ALPN
43
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-1,375,000
Closed -$54.5M
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Commodore Capital held 43 positions worth $1.47B, down 2% from $1.5B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Commodore Capital deployed $92.4M of net new capital in Q2 2024, opening 4 new positions and adding to 16 existing holdings. Its largest new stake was Alkermes: 1,375,000 shares worth $33.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Merus, an estimated $56.2M trimmed.

  • Commodore Capital's largest Q2 2024 buy was Alkermes: 1,375,000 shares worth $33.1M.
  • Commodore Capital added most to Soleno Therapeutics in Q2 2024, an estimated $53.2M increase.
  • Commodore Capital's biggest Q2 2024 reduction was Merus, cutting an estimated $56.2M.
  • Commodore Capital fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $54.5M.
  • Commodore Capital's ten largest holdings make up 64% of its $1.47B portfolio in Q2 2024.
  • Commodore Capital opened 4 new positions and closed 8 in Q2 2024.
  • Commodore Capital's portfolio value fell 2% quarter-over-quarter to $1.47B.

Based on Commodore Capital's 13F filing for Q2 2024, filed 14 Aug 2024.